drugset / Trial / NCT05030818

Cross-over Study of Coronary Risk Factors With a Polypill

NCT05030818

Phase 4 Recruiting 88 enrolled Fundación EPIC
RandomizedCrossoverOpen-labelPrevention

Summary

Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.

Timeline

Start
2022-10-14
Primary completion
2026-03-30
Completion
2026-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg
Comparator Atorvastatin Small molecule
Comparator Ramipril Small molecule